[Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin].
In Poland diagnosing of hypertension (HA) and the efficacy of treatment of this condition is still insufficient. Consideration of the concomitant metabolic disorders may help to choose the best line of therapy. To determine the incidence of HA and concomitant lipid and carbohydrate metabolism disturbances in population of one company. To assess the efficacy of monotherapy of HA and the influence of therapy on some metabolic parameters. The blood pressure was measured in 599 subjects. Patients with HA (> or = 140/90 mmHg) were treated according to metabolic parameters. Patients with fasting total cholesterol (TC) > or = 200 mg% and/or fasting glucose level > or = 110 mg% received doxazosin (D); initial dose 1 mg. The remaining patients received amlodipine (A); initial dose 5 mg. HA was found in 154 patients (27.5%). In this group, 50 of subjects were unaware of the disease, the remaining 67 (44%) were not treated or treated insufficiently. Elevated glucose and/or TC levels were found in 51% of hypertensives. After one month of treatment with A or D, the mean systolic and diastolic blood pressure decreased significantly (p = 0.001). Monotherapy was effective in 88.9% of subjects in group D and in 92.1% in group A. In group D, TC concentration decreased by 9.5% comparing to baseline (p = 0.001). The tolerance of treatment was similar in both groups. One fourth of the examined company population under medical attention of the local health service had HA. One third of HA patients were unaware of the disease. The half of patients with HA had metabolic disorders. Doxazosin and amlodipine were equally effective and well tolerated during one month of treatment. Treatment with doxazosin positively influenced the metabolic profile.